Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NASDAQ:LEGN NASDAQ:RVMD NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$12.58+2.9%$10.23$6.36▼$46.81$1.79B1.083.04 million shs2.30 million shsLEGNLegend Biotech$35.56+0.1%$37.80$27.34▼$59.62$6.53B0.261.06 million shs693,867 shsRVMDRevolution Medicines$37.01+1.5%$37.48$29.17▼$62.40$6.92B1.161.89 million shs1.09 million shsRYTMRhythm Pharmaceuticals$103.27+1.6%$81.94$44.31▼$104.87$6.86B2.38583,114 shs711,779 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics0.00%+1.62%+36.15%+7.61%-73.26%LEGNLegend Biotech0.00%-5.17%-19.57%+23.00%-37.02%RVMDRevolution Medicines0.00%+1.90%-0.56%-6.94%-18.26%RYTMRhythm Pharmaceuticals0.00%+5.80%+18.33%+65.60%+127.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYNDyne Therapeutics3.6298 of 5 stars4.51.00.00.02.85.00.0LEGNLegend Biotech3.918 of 5 stars4.54.00.00.03.41.70.6RVMDRevolution Medicines4.4023 of 5 stars4.51.00.04.73.41.70.0RYTMRhythm Pharmaceuticals3.8157 of 5 stars2.53.00.04.33.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 3.00Buy$33.80168.68% UpsideLEGNLegend Biotech 3.00Buy$72.38103.53% UpsideRVMDRevolution Medicines 3.00Buy$69.9288.93% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.57-1.64% DownsideCurrent Analyst Ratings BreakdownLatest DYN, LEGN, RVMD, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$67.008/12/2025LEGNLegend BiotechRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$75.00 ➝ $77.008/12/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$81.00 ➝ $83.008/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$57.00 ➝ $56.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $100.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $13.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$100.00 ➝ $109.00(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/ALEGNLegend Biotech$627.24M10.42N/AN/A$5.70 per share6.24RVMDRevolution Medicines$11.58M597.43N/AN/A$13.47 per share2.75RYTMRhythm Pharmaceuticals$130.13M52.71N/AN/A$0.35 per share295.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)Latest DYN, LEGN, RVMD, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1716.8316.83LEGNLegend Biotech0.304.714.57RVMDRevolution Medicines0.1311.7911.79RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%LEGNLegend Biotech70.89%RVMDRevolution Medicines94.34%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics20.77%LEGNLegend Biotech0.02%RVMDRevolution Medicines8.20%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100142.26 million112.72 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableDYN, LEGN, RVMD, and RYTM HeadlinesRecent News About These CompaniesCandriam S.C.A. Reduces Stake in Rhythm Pharmaceuticals, Inc. $RYTMAugust 23 at 7:07 AM | marketbeat.comAberdeen Group plc Increases Stake in Rhythm Pharmaceuticals, Inc. $RYTMAugust 23 at 4:34 AM | marketbeat.comRussell Investments Group Ltd. Raises Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTMAugust 23 at 4:26 AM | marketbeat.comRhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Deutsche Bank AGAugust 23 at 3:55 AM | marketbeat.comRhythm Pharmaceuticals, Inc. $RYTM Stake Lifted by Charles Schwab Investment Management Inc.August 23 at 3:55 AM | marketbeat.comAlgert Global LLC Increases Position in Rhythm Pharmaceuticals, Inc. $RYTMAugust 22 at 4:44 AM | marketbeat.comFDA Priority Review for Setmelanotide in Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM)August 21 at 9:09 AM | finance.yahoo.comRhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviewsAugust 21 at 9:09 AM | msn.comRhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotideAugust 20, 2025 | msn.comRhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic ObesityAugust 20, 2025 | globenewswire.comLord Abbett & CO. LLC Has $7.17 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 19, 2025 | marketbeat.comPNC Financial Services Group Inc. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 18, 2025 | marketbeat.comFox Run Management L.L.C. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17, 2025 | marketbeat.comE Fund Management Co. Ltd. Makes New $286,000 Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 17, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 1,500 Shares of StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Sells $333,792.00 in StockAugust 16, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CFO Hunter C. Smith Sells 24,611 SharesAugust 16, 2025 | marketbeat.com5,502 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Entropy Technologies LPAugust 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 16, 2025 | marketbeat.comJoseph Shulman Sells 3,984 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockAugust 15, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Joseph Shulman Sells 3,984 SharesAugust 14, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Buy the Dip? These Earnings Misses Offer Long-Term UpsideBy Nathan Reiff | August 7, 20254 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025Why Teradyne's 19% Rally Is Just Getting StartedBy Jeffrey Neal Johnson | August 3, 20253 Discounted Steel Stocks You Can DCA Into TodayBy Gabriel Osorio-Mazilli | July 26, 2025DYN, LEGN, RVMD, and RYTM Company DescriptionsDyne Therapeutics NASDAQ:DYN$12.58 +0.36 (+2.95%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$12.58 0.00 (0.00%) As of 08/22/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Legend Biotech NASDAQ:LEGN$35.56 +0.03 (+0.08%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$35.62 +0.05 (+0.15%) As of 08/22/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Revolution Medicines NASDAQ:RVMD$37.01 +0.53 (+1.45%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$37.40 +0.39 (+1.05%) As of 08/22/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$103.27 +1.59 (+1.56%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$103.25 -0.02 (-0.02%) As of 08/22/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access